Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire

South African Medical Journal

Volumn 96, Issue 6, 2006, Pages 526-529

  Losina, E ^a   Anglaret, X ^d,f   Yazdanpanah, Y ^e   Wang, B ^a   Toure, S ^d   Seage III, G R ^c   N'Dri Yoman, T ^d   Walensky, R P ^b   Dakoury Dogbo, N ^d   Goldie, S J ^c   Messou, E ^d   Weinstein, M C ^c   Deuffic Burban, S ^e   Salamon, R ^f   Freedberg, K A ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Programme PAC CI   (Côte d’Ivoire)

^e CENTRE HOSPITALIER DE TOURCOING   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; PLACEBO;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COTE D'IVOIRE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; POISSON DISTRIBUTION; POPULATION DISTRIBUTION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUBERCULOSIS;

ADULT; AGE DISTRIBUTION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIAL INFECTIONS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; COST OF ILLNESS; COTE D'IVOIRE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALARIA; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM INFECTIONS; MYCOSES; POPULATION SURVEILLANCE; REGRESSION ANALYSIS; RISK FACTORS; SEX DISTRIBUTION; TOXOPLASMOSIS, CEREBRAL; TUBERCULOSIS;

EID: 33745746210     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. UNAIDS Joint United Nations Programme on HIV/AIDS. Report on the global HIV/AIDS epidemic. July 2004. http://www.unaids.org/bangkok2004/GAR2004_html/GAR2004_00_en.htm (last accessed 19 April 2006).
2. Seage GR, 3rd, Losina E, Goldie SJ, et al. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. J Acquir Immune Defic Syndr 2002; 30: 421-428.
3. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353: 1463-1468.
4. Attia A, Huet C, Anglaret X, et al. HIV-1-related morbidity in adults, Abidjan, Côte d'Ivoire: a nidus for bacterial diseases. J Acquir Immune Defic Syndr 2001; 28: 478-486.
5. Miettinen O. Theoretical Epidemiology. New York: Wiley, 1985.
6. Diggle P, Heagerty P, Liang K-Y, Zar J. Analysis of Longitudinal Data. New York:Oxford University Press, 2002.
7. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36: 652-662.
8. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS 1997; 11: S43-S54.
9. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 10511-1056.
10. Gilks CF, Brindle RJ, Mwachari C, et al. Disseminated Mycobacterium avium infection among HIV-infected patients in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 195-198.
11. Thiebaut R, Chene G, Jacqmin-Gadda H, et al. Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001. J Acquir Immune Defic Syndr 2003; 33: 380-386.
12. Yazdanpanah Y, Goldie SJ, Paltiel AD, et al. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost effectiveness analysis. Clin Infect Dis 2003; 36: 86-96.
13. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364: 1428-1434.
14. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001; 15: 1143-1148.